Premium
Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia
Author(s) -
Goulden Nick,
Bader Peter,
Van der Velden Vincent,
Moppett John,
Schilham Marco,
Masden Hans O.,
Krejci Ondrej,
Kreyenberg Hermann,
Lankester Arjan,
Révész Tom,
Klingebiel Thomas,
Van Dongen Jacques
Publication year - 2003
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2003.04394.x
Subject(s) - medicine , minimal residual disease , stem cell , transplantation , oncology , disease , chemotherapy , acute lymphocytic leukemia , hematopoietic stem cell transplantation , pediatrics , lymphoblastic leukemia , leukemia , genetics , biology
Summary. Allogeneic stem cell transplantation (SCT) is a highly effective therapy for childhood acute lymphoblastic leukaemia (ALL). Concerns about unnecessary toxicity and expense mean that SCT is currently largely reserved for children who cannot be cured with chemotherapy. Not surprisingly, many such children also fail SCT. Retrospective studies have shown that a single analysis of minimal residual disease (MRD) pre‐SCT identified those at highest risk of relapse. It is now appropriate to call for the universal incorporation of standardized MRD testing into SCT protocols as the next step to maximize the clinical impact of this technology in ALL.